Autism Spectrum DisorderNCT06726187
DSM-5 Personality Disorders in Adults With Autism
An observational study of Autism Spectrum Disorder, run by Parnassia Groep at 1 site in Netherlands.
Trial summary
Rationale: Self-report measures are frequently used for research and clinical assessments of adults with autism spectrum disorder (ASD). However, there has been little research examining agreement between self-report and informant-report in this population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
- How many people
- 102 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Mar 2024to 29 Jan 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult males and females (age ≥ 18 years), clinically diagnosed with ASD by a psychologist or a psychiatrist, without intellectual disability, and their informants. ASD participants will be recruited from Sarr Autism Rotterdam, the Netherlands, specialized in psychodiagnostic assessment and treatment for children, adolescents, and adults with ASD. Sarr is part of Parnassia Groep, multisite mental health institute in the Netherlands.
Who may be able to join
- Participants were asked to identify individuals who knew them well and were capable of providing accurate descriptions of their personality traits, preferably informants that cohabited with the participants. When cohabitants were unavailable, participants were asked to identify "the person who knows you best." Additionally, eligibility of informants for inclusion required that, historically, the informant and the participant talked at least monthly and interacted face-to-face at least yearly.
- Exclusion criteria Exclusion criteria for ASD participants: (1) no ASD diagnosis, (2) current substance abuse, (3) psychotic disorders, (4) schizophrenia, (5) eating disorder, (6), mental retardation (IQ<80), (7) suicidal ideations and (8) age <18 years.
- Exclusion criteria for informants: (1) age <18 years, (2) intellectual disability, and (3) not being able to state and/or recognize psychological and problematic functioning of their participating relative with ASD.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Sarr - Parnassia Groep Antes
Rotterdam
Thomas Kramer, MSc, 088 358 1616, t.kramer@anteszorg.nl
About this study
Rationale: Self-report measures are frequently used for research and clinical assessments of adults with autism spectrum disorder (ASD). However, there has been little research examining agreement between self-report and informant-report in this population. Reliable self-report measures are essential for conducting research with and providing high quality clinical services for adults with autism spectrum disorder.
Objective: This study aims to examine the usefulness of self-report of DSM-5-TR PD traits in adults with ASD compared to informant-reports by administering the self-report screening measure of the Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
- Conditions
- Autism Spectrum Disorder
- Being tested
- Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
- Keywords
- Autism, Personality disorder
- Medical subject headings
- Autism Spectrum Disorder, Autistic Disorder, Personality Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).Other
Screening questionnaire
| Study group | Role | What they receive |
|---|---|---|
| 1 | Adults with autism spectrum disorder Receives: Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ). | |
| 2 | The relative of the adult with autism spectrum disorder Receives: Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Score SCID-5-PD
The main study parameters are the item scores on the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). The participant can score with Yes and No on the questions. The scoring parameters are 0 (No) and 1 (Yes). This is for all items. A higher score means that the participant scores on that personality item.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2024
- Study start1 Mar 2024
- Primary completion28 Jan 2027 (estimated)
- Study completion29 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 102 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Parnassia Groep
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06726187
- Sponsor's protocol ID
- 2022.56
- Status last verified
- Jul 2026
- First submitted
- 5 Dec 2024
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DSM-5 Personality Disorders in Adults With Autism
- ClinicalTrials.gov ID
- NCT06726187
- Acronym / sponsor ID
- 2022.56
- Conditions
- Autism Spectrum Disorder
- Keywords
- Autism, Personality disorder
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 102 participants (estimated)
- Lead sponsor
- Parnassia GroepUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 28 Jan 2027 (estimated)
- Study completion
- 29 Jan 2027 (estimated)
- First posted
- 10 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Self-report measures are frequently used for research and clinical assessments of adults with autism spectrum disorder (ASD). However, there has been little research examining agreement between self-report and informant-report in this population. Reliable self-report measures are essential for conducting research with and providing high quality clinical services for adults with autism spectrum disorder.
Objective: This study aims to examine the usefulness of self-report of DSM-5-TR PD traits in adults with ASD compared to informant-reports by administering the self-report screening measure of the Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).Adults with autism spectrum disorder |
| 2 | – | Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).The relative of the adult with autism spectrum disorder |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult males and females (age ≥ 18 years), clinically diagnosed with ASD by a psychologist or a psychiatrist, without intellectual disability, and their informants. ASD participants will be recruited from Sarr Autism Rotterdam, the Netherlands, specialized in psychodiagnostic assessment and treatment for children, adolescents, and adults with ASD. Sarr is part of Parnassia Groep, multisite mental health institute in the Netherlands.
Key inclusion criteria (3 listed)
- Participants were asked to identify individuals who knew them well and were capable of providing accurate descriptions of their personality traits, preferably informants that cohabited with the participants. When cohabitants were unavailable, participants were asked to identify "the person who knows you best." Additionally, eligibility of informants for inclusion required that, historically, the informant and the participant talked at least monthly and interacted face-to-face at least yearly.
- Exclusion criteria Exclusion criteria for ASD participants: (1) no ASD diagnosis, (2) current substance abuse, (3) psychotic disorders, (4) schizophrenia, (5) eating disorder, (6), mental retardation (IQ<80), (7) suicidal ideations and (8) age <18 years.
- Exclusion criteria for informants: (1) age <18 years, (2) intellectual disability, and (3) not being able to state and/or recognize psychological and problematic functioning of their participating relative with ASD.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).Screening questionnaire | Other | 1, 2 |
Primary outcome
Score SCID-5-PD
Time frame: 1 day
The main study parameters are the item scores on the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). The participant can score with Yes and No on the questions. The scoring parameters are 0 (No) and 1 (Yes). This is for all items. A higher score means that the participant scores on that personality item.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Autism Spectrum Disorder
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autism Spectrum Disorder, run by Parnassia Groep at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Score SCID-5-PD (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.